Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia

OBJECTIVES: This trial was conducted to test the effects of an alpha7 nicotinic receptor full agonist, TC-5619, on negative and cognitive symptoms in subjects with schizophrenia. METHODS: In 64 sites in the United States, Russia, Ukraine, Hungary, Romania, and Serbia, 477 outpatients (18–65 years; m...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Schizophr Bull
Main Authors: Walling, David, Marder, Stephen R., Kane, John, Fleischhacker, W. Wolfgang, Keefe, Richard S. E., Hosford, David A., Dvergsten, Chris, Segreti, Anthony C., Beaver, Jessica S., Toler, Steven M., Jett, John E., Dunbar, Geoffrey C.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2016
Assuntos:
Regular Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4753586/
https://ncbi.nlm.nih.gov/pubmed/26071208
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/schbul/sbv072
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados